Trial Profile

Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 May 2022 Results of post hoc, pooled, retrospective analysis from AFFIRM, PREVAIL and PROSPER examining the association of statin and metformin on radiographic progression-free survival , metastasis-free survival, toxicity and overall survival, published in the European Journal of Cancer
29 Dec 2021 Results of post hoc analysis assessing effect of concurrent corticosteroid use on enzalutamide-treated patients published in the Clinical Cancer Research
21 Sep 2020 Results assessing Impact of enzalutamide on patient-reported fatigue from ARCHES, PROSPER, PREVAIL, and AFFIRM presented at the 45th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com